Corum Merkez

Researchers are evaluating the effects of the drug orforglipron compared with a placebo on cardiovascular outcomes in adults who have atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). This is a Phase 3, randomized, double-blind, placebo-controlled study designed to investigate major adverse cardiovascular events over a long period. Participants will receive either orforglipron or a placebo orally. The study is event-driven and will continue until the occurrence of major cardiovascular events or up to about 5 years. The treatments are administered without revealing to participants which group they are in to ensure unbiased results. During the study, participants will be monitored for the time to the first occurrence of a major cardiovascular event. Researchers will collect data from baseline through the end of the study, which lasts approximately 5 years. Regular assessments will help evaluate the safety and effects of the treatments on cardiovascular health in this population.

This research aims to determine whether advanced hemodynamic monitoring using the MostCare system offers benefits compared to standard monitoring during propofol sedation for ERCP procedures. ERCP is a common minimally invasive procedure used to diagnose and treat biliary and pancreatic duct issues, especially in older patients who often have complications like sepsis and other health problems that make sedation management more difficult. The study focuses on detecting hemodynamic events that require clinical intervention, which are critical for maintaining proper blood flow and oxygen delivery to organs during the procedure. Participants will be monitored either with the MostCare system, which uses arterial waveform analysis through radial arterial cannulation to continuously assess detailed cardiovascular parameters, or with standard monitoring methods including non-invasive blood pressure, ECG, pulse oximetry, and BIS. The procedure will be performed under propofol sedation while patients maintain spontaneous breathing. The study will compare the number of hemodynamic events requiring intervention between these two monitoring approaches. During the study, patients will undergo ERCP with either advanced or standard monitoring. Researchers will track the occurrence of blood flow and pressure changes needing clinical management from the start of sedation until the procedure ends. The study includes assessments of vital signs and hemodynamic parameters to better understand the benefits of advanced monitoring. Participants must provide informed consent and meet eligibility criteria, with safety closely monitored throughout the ERCP procedure.

Cardiac implantable electronic devices help reduce serious heart rhythm problems and sudden cardiac death, improving survival. However, patients may face complications like device dislocation, fractures, inappropriate shocks, pocket hematoma, or infections. Restrictions on upper extremity movement after implantation can cause loss of function and reduce quality of life through decreased exercise capacity, fatigue, and weaker muscles. This study evaluates the validity and reliability of the Turkish version of the Assessment of Quality of Life and Related Events (AQUAREL) scale, developed for pacemaker patients. The study focuses on patients with pacemakers who have no complications at their last device checkup and belong to any NYHA heart failure class (I-IV). Participants will complete the Turkish AQUAREL scale, which is being tested for its accuracy and consistency in measuring quality of life related to pacemaker use. This involves assessing how well the scale captures patients' experiences and any related events. Participants will be followed for one year to assess their quality of life using the adapted scale. Researchers will monitor responses and ensure the scale reliably reflects patient wellbeing over time. The main outcome measured is the Turkish adaptation of the quality of life scale after one year, helping to understand the impact of pacemakers on daily life and supporting improved patient care.

Researchers are evaluating postoperative pain management techniques for patients undergoing total knee arthroplasty (TKA), a surgery often associated with severe pain that delays recovery and hospital discharge. This study compares the analgesic effects of two nerve block combinations: adductor canal block (ACB) with IPACK block and ACB with Biceps Femoris Short Head (BiFeS) block. Both approaches aim to reduce pain while preserving motor function, with a focus on controlling pain from both the front and back of the knee. Patients will be randomly assigned to receive either the ACB+IPACK or ACB+BiFeS block combination under spinal anesthesia. The ACB involves an ultrasound-guided injection of bupivacaine around the femoral artery, while the IPACK and BiFeS blocks target nerves supplying the posterior knee capsule with separate ultrasound-guided injections. Following nerve blocks, spinal anesthesia is administered, and all patients receive standardized postoperative pain management including paracetamol and patient-controlled tramadol. Participants will be monitored for pain intensity at rest and during movement at multiple time points up to 24 hours after surgery, opioid consumption, motor function through quadriceps strength testing, and side effects such as nausea and vomiting. Additional outcomes include time to first mobilization, quality of recovery scores, and vital signs. This detailed assessment aims to determine which nerve block combination provides better pain control and recovery experience after TKA.

Hip fractures are a common and serious issue in older adults, often causing significant health problems and disability. This research compares two ultrasound-guided nerve block techniques, the suprainguinal fascia iliaca block (SIFI) and the quadro-iliac plane block (QIPB), for managing pain after hip fracture surgery. Both techniques aim to reduce opioid use and improve pain control, but no direct comparison between them has been done before. The study involves performing either the SIFI or QIPB nerve block before surgery. The SIFI block targets nerves around the anterior superior iliac spine by injecting local anesthetic between the iliacus muscle and fascia iliaca. The QIPB is performed near the L3 vertebra to block nerves around the iliac wing and surrounding muscles. Both blocks use ultrasound guidance and a standardized dose of local anesthetic to ensure safety and effectiveness. Participants will be monitored for pain levels 24 hours after surgery using a numeric rating scale. Researchers will assess postoperative opioid consumption and evaluate the effectiveness of each nerve block in controlling pain. The study includes careful follow-up with assessments, ensuring participants understand and can use pain measurement tools and devices. The goal is to provide clearer guidance on the best nerve block method to improve recovery after hip fracture surgery.

Researchers are evaluating the effects of maridebart cafraglutide, given alongside standard care, in reducing heart failure events such as hospitalizations, urgent visits, cardiovascular deaths, and improving symptoms in people with heart failure who have preserved or mildly reduced ejection fraction and are obese. This is a global phase 3, multicenter trial with a two-part design including a double-blind period followed by an open-label extension. The first part will end once around 850 key events have been recorded. Participants will receive either maridebart cafraglutide or a placebo, both administered by injection under the skin. The study includes an initial randomized, double-blind phase and a later open-label extension where all participants may receive the active treatment. The trial is designed to monitor participants over time to assess the safety and effects of the treatment compared to placebo. During the trial, participants will undergo assessments including monitoring for cardiovascular events, heart failure symptoms, and laboratory tests such as NT-proBNP levels. Researchers will track time until the first occurrence of cardiovascular death or heart failure events over approximately 35 months. Safety evaluations, adherence to treatment, and ongoing health status will be followed throughout the study period.

Researchers are investigating how common misophonia and hyperacusis are among teachers and how these sound sensitivities might be linked to work-related stress. Misophonia involves a low tolerance to everyday sounds like chewing or tapping, while hyperacusis is an increased sensitivity to normal sounds that cause discomfort. Teachers may be more prone to these issues due to constant exposure to various classroom noises. The study will include teachers aged 22 to 45 who are actively working in preschool, elementary, middle, or high schools and who have no diagnosed hearing loss, chronic illnesses, or psychological disorders. Participants will fill out a form about their health and work background, then complete two validated questionnaires: the Khalfa Hyperacusis Scale to assess hyperacusis and the AMISOS-R to measure misophonia. Participants will be assessed once at the start of the study to determine the prevalence of these auditory sensitivities. Researchers will analyze the data to better understand the sensory challenges teachers face in educational settings and how these may contribute to occupational stress. The goal is to support future efforts to improve the working conditions and well-being of teachers.

This research aims to assess the impact of respiratory physiotherapy on diaphragm thickness in patients receiving mechanical ventilation in the intensive care unit (ICU). Diaphragm thinning and dysfunction caused by mechanical ventilation can complicate the removal of the breathing tube and increase the risk of respiratory failure, prolonged ventilator use, and higher ICU mortality. The study focuses on whether respiratory physiotherapy can protect or improve diaphragm muscle structure and function to help optimize the process of weaning patients from mechanical ventilation and contribute scientific knowledge to respiratory rehabilitation. Participants receive either standard ICU physiotherapy once daily for 15 to 20 minutes or standard ICU physiotherapy combined with neuromuscular electrical stimulation (NMES) applied twice daily to the diaphragm area. These interventions aim to evaluate the effects of respiratory physiotherapy on diaphragm thickness using ultrasonography, a non-invasive imaging method. The study is prospective and observational, with controlled groups to compare treatment effects. During the study, changes in diaphragm thickness are measured at the start of mechanical ventilation, on day 5, day 7, or at discharge—whichever occurs first. Patients are monitored through ultrasound imaging to assess diaphragm muscle changes. The research tracks the impact of respiratory physiotherapy on preventing ventilator-associated diaphragm dysfunction and improving clinical outcomes related to ventilator weaning and ICU stay. The total participation period includes these early ICU days while the patient is mechanically ventilated.

Researchers are studying how seasonal changes affect physical activity levels in people with heart failure who have cardiac implantable electronic devices. This observational study focuses on patients diagnosed with heart failure due to ischemic or non-ischemic cardiomyopathy and who are classified as New York Heart Association (NYHA) Class I, II, or III. The goal is to understand variations in physical activity throughout the year. The study involves monitoring physical activity objectively using the patients' implantable cardiac devices across all four seasons: spring, summer, autumn, and winter. Participants will be followed for one year without any additional interventions, allowing researchers to observe natural changes in activity related to seasonal differences. Participants will be evaluated every three months during the study year to measure both their objective physical activity levels recorded by the devices and their subjective reports of activity. The study includes assessments in each season to capture seasonal variation. Researchers will also monitor safety and cooperation throughout the study period.

This research aims to assess the effects of a 20-minute second-level Reiki treatment applied for four consecutive days on pain intensity and quality of life in patients undergoing hemodialysis (HD). The study also compares these results with previous findings from first-level Reiki treatments conducted as part of a doctoral thesis. Hemodialysis patients often experience pain and reduced quality of life due to chronic kidney disease and its treatments, making effective pain management vital. Reiki, a non-invasive energy therapy, may offer a complementary approach to improve these symptoms alongside standard care. Participants are randomly assigned to either receive second-level Reiki sessions or a sham Reiki treatment. The Reiki group will have daily 20-minute distance Reiki sessions in the evening for four days, while the sham group will be informed they are receiving distant energy treatment but will not receive actual Reiki. All patients will continue their routine hemodialysis treatments during the study. The Reiki sessions are administered by a trained researcher following a specific application protocol. Throughout the study, pain severity and quality of life will be measured before and after the intervention using the Visual Analog Scale for Pain and the Kidney Disease Quality of Life Scale (KDQOLTM-36). Assessments will occur face-to-face at the hemodialysis centers initially and three weeks post-intervention. Additionally, psychodynamic responses during Reiki sessions will be evaluated by blinded assessors via telephone. Data analysis will use appropriate statistical tests to determine the impact of the Reiki treatments on the participants' pain and quality of life.